Isabel Meister

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1946690/publications.pdf

Version: 2024-02-01

17	659	13 h-index	17
papers	citations		g-index
20	20	20	1077
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with SchistosomaÂmansoni and S.Âhaematobium and Lao adults infected with OpisthorchisÂviverrini. Journal of Pharmacokinetics and Pharmacodynamics, 2022, , 1.	0.8	3
2	High-Precision Automated Workflow for Urinary Untargeted Metabolomic Epidemiology. Analytical Chemistry, 2021, 93, 5248-5258.	3.2	21
3	Untargeted LC-MS Metabolomics for the Analysis of Micro-scaled Extracellular Metabolites from Hepatocytes. Analytical Sciences, 2021, 37, 1049-1052.	0.8	6
4	Defining the Scope of Exposome Studies and Research Needs from a Multidisciplinary Perspective. Environmental Science and Technology Letters, 2021, 8, 839-852.	3.9	55
5	Correlation-Based Deconvolution (CorrDec) To Generate High-Quality MS2 Spectra from Data-Independent Acquisition in Multisample Studies. Analytical Chemistry, 2020, 92, 11310-11317.	3.2	46
6	Challenges, progress and promises of metabolite annotation for LC–MS-based metabolomics. Current Opinion in Biotechnology, 2019, 55, 44-50.	3.3	253
7	Creating a Reliable Mass Spectral–Retention Time Library for All Ion Fragmentation-Based Metabolomics. Metabolites, 2019, 9, 251.	1.3	30
8	Pooled Population Pharmacokinetic Analysis of Tribendimidine for the Treatment of $\langle i \rangle$ Opisthorchis viverrini $\langle i \rangle$ Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	6
9	Evaluation of a novel micro-sampling device, Mitra™, in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural Cà te d'lvoire. Journal of Pharmaceutical and Biomedical Analysis, 2018, 151, 339-346.	1.4	23
10	Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial. Lancet Infectious Diseases, The, 2018, 18, 155-161.	4.6	26
11	Pharmacokinetics of Praziquantel in Schistosoma mansoni- and Schistosoma haematobium-Infected School- and Preschool-Aged Children. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
12	LC-MS-Based Metabolomics of Biofluids Using All-Ion Fragmentation (AIF) Acquisition. Methods in Molecular Biology, 2018, 1730, 45-58.	0.4	17
13	Efficacy and safety of praziquantel against light infections of <i>Opisthorchis viverrini</i> : a randomised parallel single blind dose-ranging trial. Clinical Infectious Diseases, 2017, 64, ciw785.	2.9	15
14	Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004700.	1.3	17
15	Development and validation of an enantioselective LC–MS/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 81-88.	1.4	25
16	Activity of Praziquantel Enantiomers and Main Metabolites against Schistosoma mansoni. Antimicrobial Agents and Chemotherapy, 2014, 58, 5466-5472.	1.4	85
17	Efficacy and pharmacokinetics of OZ78 and MT04 against a natural infection with Fasciola hepatica in sheep. Veterinary Parasitology, 2013, 198, 102-110.	0.7	13